For years, there was no stopping Novo Nordisk, the Danish drugmaker behind Ozempic. Its diabetes drug became a cultural phenomenon for its ability to induce drastic weight loss while also reducing the risk of heart attacks and other serious diseases in people with obesity. Its potential to transform the health care industry made it a darling of the stock market, surging to become the most valuable company in Europe.
Then, suddenly, its fortunes took a turn.
Novo Nordisk’s share price has plummeted more than 50 percent this year, pushing it out of the top ten list of Europe’s most valuable companies. The company bewildered analysts in May when it abruptly said it would replace its chief executive, and it has seemed unable to keep ahead of competition from the American drugmaker Eli Lilly and the prevalence of cheap copycat versions.
“The market’s got no patience for Novo,” said Gareth Powell, the head of health care at Polar Capital, a fund manager. “Sentiment is absolutely dire.”
It has been a stunning reversal for the company behind a drug that physicians once called a game changer. On Wednesday, Novo Nordisk reported $24 billion in global sales in the first six months of the year, but reiterated that it expects growth to slow in the rest of the year, which it first flagged in a profit warning last week. The company’s stock tumbled more, as analysts and investors expressed doubts about whether there was much the company could do to revive its prospects in the short term.
Novo Nordisk is “a company with incredible history and capabilities, and they’ve got a pipeline,” Mr. Powell said. “It’s just the market’s putting zero value on it.
The post How Ozempic’s Maker Lost Its Shine After Creating a Wonder Drug appeared first on New York Times.
